HALO vs. PFE
HALO (Halozyme Therapeutics, Inc.) and PFE (Pfizer Inc.) are both stocks. Both are in the Healthcare sector — HALO in Biotechnology, PFE in Drug Manufacturers - General. Over the past 10 years, HALO returned 22.84%/yr vs 2.11%/yr for PFE. At a 0.28 correlation, their price movements are largely independent.
Performance
HALO vs. PFE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HALO achieves a 3.27% return, which is significantly lower than PFE's 8.79% return. Over the past 10 years, HALO has outperformed PFE with an annualized return of 22.84%, while PFE has yielded a comparatively lower 2.11% annualized return.
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
PFE
- 1D
- 0.15%
- 1M
- 1.79%
- YTD
- 8.79%
- 6M
- 4.79%
- 1Y
- 14.27%
- 3Y*
- -7.78%
- 5Y*
- -3.35%
- 10Y*
- 2.11%
HALO vs. PFE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
PFE Pfizer Inc. | 8.79% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
Correlation
The correlation between HALO and PFE is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Mar 16, 2004 | 0.28 |
Fundamentals
HALO:
$8.54B
PFE:
$150.21B
HALO:
$2.87
PFE:
$1.31
HALO:
24.26
PFE:
19.98
HALO:
2.74
PFE:
0.36
HALO:
5.61
PFE:
2.36
HALO:
38.88
PFE:
1.67
HALO:
$1.51B
PFE:
$63.32B
HALO:
$1.23B
PFE:
$43.91B
HALO:
$980.05M
PFE:
$16.94B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HALO vs. PFE — Risk / Return Rank
HALO
PFE
HALO vs. PFE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HALO | PFE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.37 | ||
| Sortino ratioReturn per unit of downside risk | +0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.12 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.14 | 1.13 | +0.01 |
| Martin ratioReturn relative to average drawdown | 2.16 | 2.27 | -0.11 |
Loading charts...
Drawdowns
HALO vs. PFE - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, which is greater than PFE's maximum drawdown of -69.24%. Use the drawdown chart below to compare losses from any high point for HALO and PFE.
Loading charts...
Drawdown Indicators
| HALO | PFE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.26% | -69.24% | -5.02% |
Max Drawdown (1Y)Largest decline over 1 year | -24.13% | -11.47% | -12.66% |
Max Drawdown (3Y)Largest decline over 3 years | -33.92% | -40.43% | +6.51% |
Max Drawdown (5Y)Largest decline over 5 years | -49.06% | -58.96% | +9.90% |
Max Drawdown (10Y)Largest decline over 10 years | -49.06% | -58.96% | +9.90% |
Current DrawdownCurrent decline from peak | -14.44% | -45.68% | +31.24% |
Average DrawdownAverage peak-to-trough decline | -31.88% | -22.90% | -8.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.73% | 5.70% | +7.03% |
Volatility
HALO vs. PFE - Volatility Comparison
Halozyme Therapeutics, Inc. (HALO) has a higher volatility of 8.94% compared to Pfizer Inc. (PFE) at 5.07%. This indicates that HALO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HALO | PFE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.94% | 5.07% | +3.87% |
Volatility (6M)Calculated over the trailing 6-month period | 24.02% | 14.62% | +9.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.20% | 23.84% | +6.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.42% | 25.48% | +13.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.88% | 23.89% | +18.99% |
Dividends
HALO vs. PFE - Dividend Comparison
HALO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.56%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PFE Pfizer Inc. | 6.56% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
HALO vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. PFE - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
Frequently Asked Questions
HALO and PFE have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HALO has higher volatility (8.94%) compared to PFE (5.07%). In terms of maximum drawdown, HALO dropped -74.26% vs PFE's -69.24%.
HALO currently has the higher Sharpe Ratio (0.91 vs 0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HALO and PFE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer